Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs...

|By:, SA News Editor

Goldman's Terence Flynn says a study published in a medical journal suggests branded VEGF drugs such as Regeneron's (REGN +2.7%) Eylea "are superior to off-label Avastin." In the cited study, patients on Lucentis realized a 13 letter improvement in vision versus an 11 letter improvement for those on Avastin.